Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropanicant in Major Depressive Disorder
NCT06836063Phase 2Completed
- Sponsor
- Suven Life Sciences
- Start
- Jul 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Ropanicant in major depressive disorder (MDD) (3 arms), sponsored by Suven Life Sciences. Primary endpoint: Montgomery-Asberg Depression Rating Scale at 6 weeks. Started Jul 2025; status: completed.
02
Drugs
Ropanicant
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06836063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06836063.